Background and Purpose-Middle cerebral artery M2-segment occlusions represent an important subgroup of patients with acute stroke with large-vessel occlusion. The safety of mechanical thrombectomy, especially contact aspiration (CA), in such distal intracranial occlusions is still under debate. We compared reperfusion, adverse events, neurological recovery, and functional outcome of patients with isolated M2 occlusions according to the first-line strategy mechanical thrombectomy devices (CA versus stent retriever [SR]).
O nly a limited number of patients with middle cerebral artery M2 occlusion strokes were included in trials. They nevertheless represent an important subgroup of patients with large-vessel occlusion. Although more data are needed to address the question of mechanical thrombectomy (MT) benefit for M2 occlusions, in practice, MT is usually performed in
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February 2018 these cases. 1 The safety of MT in M2 occlusions remains a concern, and stent retriever (SR) may be more difficult to maneuver in the distal arteries. The comparison of results of contact aspiration (CA) versus SR is limited to date. 2 The aim of this post hoc study was to compare reperfusion, adverse events, neurological recovery, and functional outcome according to the first-line strategy in patients with an isolated M2 occlusion within the framework of the ASTER trial (Contact Aspiration Versus Stent Retriever for Successful Revascularization).
Methods

Patient Selection
Patient eligibility and methods of ASTER have been reported previously. 3 In the present analysis, we included patients with an M2-segment middle cerebral artery occlusion on the initial angiogram, according to the core laboratory analysis. The M2 segment was defined as the vertical middle cerebral artery branches in the Sylvian fissure originating at the genu and extending to the next genu at the level of the operculum. If the anterior temporal artery arises from the horizontal M1 segment, is not considered an M2 branch. 4 Institutional review board approval and written informed consent was obtained. Treatment modalities are detailed in the online-only Data Supplement. The data that support the findings of this study are available from B.L. on reasonable request.
Outcomes
The primary outcome was successful reperfusion defined as a modified Thrombolysis in Cerebral Infarction (mTICI) score of 2b or 3 at the end of all endovascular procedures. Secondary technical efficacy outcomes were mTICI score 2b/3 at the end of firstline strategy, mTICI score 2c/3, and mTICI score 3 at the end of first-line procedure and at the end of all procedures. Secondary clinical efficacy outcomes were the degree of disability assessed by the modified Rankin Scale score at 90 days, change in National Institutes of Health Stroke Scale score and Alberta Stroke Program Early Computed Tomography score at 24 hours. Safety included procedure-related serious adverse events, intracranial hemorrhage on imaging at 24 hours, and death because of any cause at 90 days. All angiographic and neuroimaging readings were performed at the imaging core laboratory, blinded to procedure allocation.
Statistical Analysis
Categorical variables were expressed as frequencies and percentages and continuous as mean (SD) or median (interquartile range) for nonnormal distribution. Normality of distributions was assessed graphically and by using the Shapiro-Wilk test. Baseline characteristics were described in each treatment group, and absolute standardized differences were calculated to evaluate baseline imbalance; absolute standardized differences >20% were interpreted as meaningful imbalance. Efficacy outcomes were compared between the 2 treatment groups using a generalized linear mixed model adjusted for the randomization stratification variables by including thrombolysis as a fixed effect and center as a random effect (further details in the online-only Data Supplement). No adjustment for multiple testing was applied, and thus results are considered exploratory. Statistical testing was conducted at the 2-tailed α level of 0.05. Data were analyzed using the SAS software package, release 9.4 (SAS Institute, Cary, NC).
Results
Among 381 patients, 79 were included in the present study ( Figure I in the online-only Data Supplement); 48 were allocated to the CA group and 31 to the SR group. There were several meaningful between-group differences in baseline characteristics, the greatest difference being in admission systolic blood pressure (absolute standardized differences, 48%; Table I Figure III in the online-only Data Supplement). Mortality at 90 days occurred in 9 patients (19.6%) in the CA group and in 1 patient (3.3%) in the SR group (P=0.078). Procedure-related adverse events occurred in 7 (14.6%) patients with CA and in 3 (9.7%) patients with SR (P=0.73). Symptomatic intracranial hemorrhage occurred in 4 patients overall.
Discussion
Our study suggests that effectiveness and safety should not be an argument in the choice of the first-line strategy for MT of isolated M2 occlusions because we observed no significant differences on reperfusion, infarct volume, clinical outcome, or adverse events. However, we found a difference of borderline significance in early imaging and clinical favorable evolution, as well as a lower 90-day mortality rate, in patients treated primarily with SR. In addition, a rescue therapy was used more frequently in CA-assigned patients, probably because of a lower mTICI 3 rate in CA group after the first-line strategy alone.
Similar outcomes were published after MT of M2 occlusions. In a retrospective multicenter study including 117 patients with M2 occlusion treated with MT, 56% of patients achieved a 90-day modified Rankin Scale score ≤2, whereas the mTICI 2b/3 rate was 85%, and parenchymal hematoma occurred in 13%. 5 The authors observed no difference between 2 approaches (51 patients in CA group and 62 in SR group). There was no difference in reperfusion and 90-day modified Rankin Scale ≤2 rates in another small retrospective study; however, SR provided faster reperfusion. 2 Further studies are warranted.
Limitations
Our study was not powered to analyze the differences in outcomes for isolated M2 occlusions after MT, and randomization was not performed according to the occlusion location in ASTER. Despite randomization, baseline characteristics are not well balanced between 2 groups, as a higher admission systolic blood pressure level in CA group explaining its potential unfavorable outcome. However, the present analysis is the largest prospective study comparing the 2 most commonly used MT approaches, including core laboratory, within the framework of a randomized trial. 
